Radiotherapy plus camrelizumaband irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.

[1]  Sung-Bae Kim,et al.  Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Kong,et al.  Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial , 2022, BMJ.

[3]  Qi Li,et al.  Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. , 2022, Cancer cell.

[4]  R. Zheng,et al.  Cancer incidence and mortality in China, 2016 , 2022, Journal of the National Cancer Center.

[5]  Ying Cheng,et al.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. , 2021, JAMA.

[6]  C. Mothersill,et al.  Low dose ionizing radiation and the immune response: what is the role of non-targeted effects? , 2021, International journal of radiation biology.

[7]  Weihu Wang,et al.  RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma. , 2021, Future oncology.

[8]  Quanren Wang,et al.  Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma , 2021, The oncologist.

[9]  B. Bednarz,et al.  Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain , 2021, Radiation Research.

[10]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[11]  M. Shah,et al.  KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma , 2021, Future oncology.

[12]  Sung-Bae Kim,et al.  Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Welsh,et al.  Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma , 2020, Journal for ImmunoTherapy of Cancer.

[14]  Joe Y. Chang,et al.  Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial , 2020, Journal for ImmunoTherapy of Cancer.

[15]  T. Illidge,et al.  Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations , 2020, Radiation Oncology.

[16]  I. Mills,et al.  Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model , 2020, British Journal of Cancer.

[17]  Yuquan Wei,et al.  Effect of low-dose radiotherapy on abscopal responses to hypofractionated radiotherapy and anti-PD1 in mice and NSCLC patients. , 2020, International journal of radiation oncology, biology, physics.

[18]  Y. Ba,et al.  Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. , 2020, The Lancet. Oncology.

[19]  L. Collette,et al.  Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. , 2020, The Lancet. Oncology.

[20]  Sung-Bae Kim,et al.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[21]  J. Aerts,et al.  Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[22]  R. Weichselbaum,et al.  Integration of radiotherapy and immunotherapy for treatment of oligometastases. , 2019, The Lancet. Oncology.

[23]  Ying Cheng,et al.  Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial , 2019, Cancer communications.

[24]  J. Reichert,et al.  Antibodies to watch in 2018 , 2018, mAbs.

[25]  P. Iyengar,et al.  Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[26]  Henry Knipe,et al.  Oligometastases , 2016, Radiopaedia.org.

[27]  Jing Huang,et al.  Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma , 2015, Thoracic cancer.

[28]  Y. Liu,et al.  Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. , 2016, American journal of cancer research.

[29]  S. Demaria,et al.  Role of Local Radiation Therapy in Cancer Immunotherapy. , 2015, JAMA oncology.

[30]  K. Iwamoto,et al.  Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.